ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IBIO vs XLO // PIOTROSKI F-SCORE QUALITY

iBio Inc. (NASDAQ) VS. Xilio Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IBIO 1 — XLO 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBIO VS. XLO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IBIO XLO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -10.78% — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 77.80% 180.00% -102.20 XLO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 4/9 4/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.2 42.1 -1.88 XLO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $52.3M $51.1M $1.2M IBIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IBIO REV XLO REV IBIO GROSS % XLO GROSS % IBIO FCF XLO FCF
FY 2025 $400.0K $43.8M — — -$15.3M -$5.5M
FY 2024 $225.0K $6.3M — — -$18.8M -$18.4M
FY 2023 $0 $0 — — -$30.4M -$68.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBIO // BETA —
XLO // BETA —